Incyte Corp

NASDAQ: INCY
$80.58
-$0.95 (-1.2%)
Closing Price on November 12, 2024

INCY Articles

Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Monday was a relatively positive day for the three major U.S. exchanges, but trading volumes were low as this is a truncated trading week. Crude oil was negative on the day. The S&P 500 sectors...
The S&P 500 index closed up about 0.5% Wednesday on a day that saw all three major indexes finish on the up side.
Overall Monday was a relatively flat day for the broad markets. Despite crude oil sliding lower on the day, Oil & Gas stocks were relatively mixed, with the likes of Exxon actually posting a...
The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care sector is on the move.
24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could have the biggest boom or bust at the conference.
Although Wednesday was the worst trading day that the markets have seen in 2016, Thursday the broad markets made a handy recovery. All of the sectors were positive in the index with only a few...
The top analyst upgrades, downgrades and other research calls on Friday include Ambac, Bed Bath & Beyond, General Electric, Tiffany and Trade Desk.
When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment.
The top analyst upgrades, downgrades and initiations seen from Monday include Canadian Solar, Constellation Brands, Eli Lilly, Incyte, McDonald's and Snap.
With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high valuations and some messy geopolitical issues, it makes sense for investors to look...
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
The first quarter's top-performing stocks in the S&P 500 index included two pharmaceutical firms, an electricity generator, a video game maker and a media company.
24/7 Wall St. tracked the best performing members of the S&P 500 Index on a year-to-date basis. It turns out that seven of the 500 stocks have gains of between 30% and 50%. That's no small...